Stocks to invest in
I usually don’t give away my best stock idea but today I am going to make an exception. I don’t give away my best idea because I don’t want to alienate our paying subscribers. Also, most investors don’t appreciate the value of a good investment idea unless they pay for it. More than 50 thousand people downloaded and read my last free report, yet only a tiny fraction of these people acted on it. That’s why I try to get people pay for our newsletters and I share ONLY ONE FREE REPORT per year.
By the way, my name is Ian Dogan. I have a PhD in financial economics. I am Insider Monkey’s co-founder and research director. I develop quantitative investment strategies that identify the best small-cap stock picks of hedge funds and corporate insiders.
The last free report I shared on Insider Monkey was published a year ago on April 17th, 2015. Since then we made this report available at the bottom of each article we publish on our site. Even today, if you open any article on our site (including this article) you will see our free report “Biotech Insider Alert – $5 Stock To Hit $40“. You can download a copy of this report here if you haven’t already done so.
Biotech stocks performed terribly since I published this report. SPDR S&P Biotech ETF (XBI) lost 30% of its value during this period. I want you to keep in mind that it is extremely difficult to pick a winning stock from an industry that plunged into a severe bear market. So, what was our extremely promising $5 stock and how did it perform in this severe biotech bear market?
The stock was a $60 million market cap Adamis Pharmaceuticals (ADMP) that was trading at $4.88 on April 17th, 2015. Adamis managed to return 70% through April 29th. If you invested $10,000 on this stock when we published this FREE report, your investment could have been $17,000 today. If you are an average biotech investor who invested in the biotech ETF XBI, your investment would have gone down to $7000.
Don’t get me wrong. It wasn’t easy to make 70% in one year and beat our benchmark by 100 percentage points. Most investors don’t have the patience and discipline to hold on to a stock after a 20-30% decline. Adamis lost nearly 20% of its value in the first 6 months following the publication of our report and traded at $4 a share. The gains came after December when the company resubmitted its “New Drug Application” for its Epinephrine Pre-filled Syringe (“PFS”) product candidate.
Last year we picked ADMP as our best investment idea in anticipation of the approval of its PFS product. Our time frame for this thesis was between 6 and 18 months. We now know that FDA will make a decision on June 4, 2016.
This brings us to “my #1 best idea in the world with a 10% guaranteed return in one month”. The idea is still Adamis Pharmaceuticals (ADMP). Yeah, I know you feel like you missed the boat by not buying this stock last year when it was trading below $5. It is true that the easy gains are made but I believe there is a 80-90% probability that FDA will approve Adamis’ new drug application and the stock will go above $9 in early June. I guarantee this. If Adamis fails to break through $9.10 by the end of June 6th, I will refund 100% of your subscription fee to our premium monthly healthcare newsletter.
Adamis is my best short-term idea. However, if you are a patient investor and looking for the next Adamis that can double in a year, you will have access to two fantastic ideas when you subscribe to our premium monthly healthcare newsletter. Right now we have a promotion going on. You can subscribe to our monthly healthcare newsletter for only $299/year, a discount of 33%. This is a limited time offer and expires on May 10th. Sign up NOW.
– Stocks to invest in